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This presentation will provide an overview of the broad set of publicconcerns about animal biotechnology that have been expressed both in 
the U.S. and in the European Community (EC). I will also assess the mean-
ing of biotechnology disputes for recent policy decisions concerning regulation.
The Bush Administration policy on regulating biotechnology defined 
and limited the scope of statutory authority of federal agencies. To facilitate 
federal approval of new products and, thereby, to enhance the competitive-
ness of the American biotechnology industry, the Council on Competitiveness 
in the Office of the Vice President limited regulatory authority to the issue 
of “reasonably foreseeable risk to health or the environment.” The Council’s 
policies for biotechnology for the 1990s would focus on encouraging eco-
nomic competitiveness over other concerns.
Limiting regulation to narrow questions of risk was welcomed by some 
for its economic benefits, but it was promptly attacked by others for ignor-
ing the troublesome implications of creating genetically engineered organ-
isms. These implications have been the source of continuing disputes over 
issues extending far beyond the question of “reasonably foreseeable risk.” 
The range of these issues suggests that the narrowly focused Bush adminis-
tration policy and its arguments for the urgency of economic competitive-
ness are unlikely to ease the growing tensions over biotechnology develop-
ments and, indeed, may increase the “intuitive mistrust” that has long 
marked public attitudes towards genetic manipulation.
T H E  P U B L I C  A N I M A L  P A T E N T I N G  D I S P U T E S
The patenting of living organisms has become an important focus of these 
tensions in both the U.S. and in Western Europe. A 1987 decision by the U.S. 
Patent and Trademark Office held that animals altered by genetic engineer-
ing were patentable. However, the European Patent Office decided, in 1989, 
that it could not grant patents on animals under the terms of the European *
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Patent Convention. Currently the issue is the focus of intense debate in sev-
eral European countries. It is also the subject of debate in the European Par-
liament as it responds to a legal appeal against the patenting of a genetically 
engineered human hormone called Relaxid, and considers legislation on the 
legal protection of biotechnological inventions.
Normally business in a patent office is viewed as technical and hardly 
a subject for public debate, but the granting of patents to living inventions 
has spurred a storm of protest from a broad range of interests. The outraged 
response reveals the complex set of concerns that has more broadly marked 
public attitudes towards genetic engineering and raises questions about the 
viability of limiting the scope of regulation.
The debate over the patenting of genetically engineered animals offers 
a window on the range of concerns that have followed the diffusion of new 
biotechnology developments since the 1970s when recombinant DNA re-
search evoked fears of the escape of lethal organisms into the environment. 
Subsequently, critics have mobilized to oppose the field testing of geneti-
cally engineered bacteria designed to inhibit frost damage, the creation of 
genetically altered fish, the development of disease-resistant crops, the use 
of bovine growth hormones and many other biotechnology applications. 
Such disputes are likely to amplify in response to advances in human genet-
ics, especially as scientists seek to patent human genetic material.
To explore the nature and diversity of these concerns, I find it useful to 
present the views expressed by participants in a Congressional hearing and 
by the literature disseminated by several European Green groups. From 
there, I am able to provide suggestions regarding the kinds of strategies that 
may help to develop acceptable policies concerning a technology with sig-
nificant economic and ethical implications.
Disputes over genetic manipulation of animals have been smoldering 
in both the U.S. and Western Europe since the 1980 Supreme Court ruling 
on patenting living organisms. Researchers in both academia and industry 
have maintained that patent protection of transgenic animals is essential for 
the development and diffusion of promising medical and agricultural ben-
efits to society and, in its 1987 decision, the U.S. Patent and Trademark Of-
fice concurred. After this decision, applications flooded the Office, but so 
too did protests—from farmers, religious leaders, environmentalists and 
animal rights activists who were concerned about the consequences of this 
technology. Farmers believe that the high cost of raising, breeding and own-
ing genetically altered livestock would cause small farm foreclosures. Others 
believe that patenting animals is immoral because it defines complex, living 
organisms as profit-making machines. Still others worry that the institu-
tional collaborations between industry and universities involved in the de-
velopment of biotechnology will compromise the quality and integrity of 
research.
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These issues were played out in the U.S. at Congressional hearings and in 
Europe in appeals against the European Economic Community (EEC) di-
rective on biological patents. These animal patent disputes aired a set of 
controversial questions: Would the effects of biotechnology on agricultural 
production destroy small farms unable to pay royalties? What does patent-
ing imply for the integrity of species and the moral obligation to preserve 
nature? What would be the effect of patenting on scientific research? The 
decision to patent transgenic animals has generated economic speculations 
about the current pace of research in internationally competitive scientific 
fields and the impact of new technology on the traditional farm sector. Bio-
technology and pharmaceutical firms regard patent protection as essential 
to fueling invention by the private sector, particularly because federal sup-
port for agricultural research has declined steadily since the second World War.
American corporate interests, for example, view patenting as necessary 
if the U.S. is to effectively compete worldwide for the products emerging 
from biotechnology research. In the Congressional hearings of 1988, Rich-
ard Godown, president of the Industrial Biotechnology Association (IBA) 
pointed out that: “A Japanese company has genetically engineered silk-
worms to produce a hepatitis vaccine” and “the United Kingdom and Ire-
land may be in the lead in animal biotechnology.” Even China, he observed, 
is already test marketing low-fat pigs produced by growth hormone injec-
tion. Another scientist asked the Congress: “How are our farmers going to 
feel when that ham, which is 70 percent fat-free, comes here in cans and is 
sold in the United States?”
Farmers, however, are deeply divided on the issue. The American Farm 
Bureau Federation, representing 3.5 million member families, has long fa-
vored free market policies and innovation in farming technology, and em-
phasizes the potential benefits of genetic engineering. They anticipate that 
new biotechnologies will reduce farm costs and expand the utilization of 
farm products—transgenic livestock would grow faster and be brought to 
market sooner than conventional breeds; genetically lean and disease-resis-
tant animals would provide healthier meat to consumers than the fatty live-
stock injected with antibiotics sold today. According to the Farm Bureau, 
patents and exclusive licensing to the private sector were the only ways to en-
sure the development of biotechnology discoveries and the commercialization 
of new agricultural products.
Other farmers’ groups, however, oppose animal patents on the grounds 
that large corporations would usurp the ownership of livestock—a resource 
presently controlled by the farmers themselves. These farmers predict dire 
consequences for traditional breeding techniques and they worry about the 
continued demise of the small family farm. “Will animal patenting result in 
greater concentration in those who produce breeding stock as it has created 
in the seed industry in recent years? ...We are an industry that has seen our
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numbers drop drastically in the past two years and there are not enough of 
us left to take chances on a major mistake,” said the president of the Na-
tional Farmers Union (NFU) in his testimony at the hearings. Representing 
about 300,000 farming families, this organization believes that “The small 
business structure of the family farm is the nation’s bulwark against com-
munism and fascism. It is essential to the democratic way of life.” This has 
frequently translated into opposition to technological changes that would 
harm the small farmer.
The National Farmers Organization, the American Agriculture Move-
ment, the Coalition to Save the Family and the League of Rural Voters 
joined the NFU in its concerns about the economic implications of genetic 
engineering. They played on the popular myth of the family farm as a foun-
dation of American values and the fear that patents would force further cor-
porate concentration of agriculture. European groups, for example, the 
UK’s Compassion in World Farming, oppose patenting for similar reasons. 
“The losers would be the smaller plant and animal breeders who are not 
able to embark on research or pay the royalties....This makes the farmer 
more dependent on the chemical industry that currently controls biotech-
nology.” It would further divide the farming community into winners 
(those who can afford to adopt these expensive technologies) and losers 
(those who cannot). In Europe, as in the U.S., opposition focused on issues 
of equity, drawing from the growing concern about monopolistic practices 
in the agribusiness, pharmaceutical and chemical sectors.
While farm interests have focused on the economic consequences of 
animal patenting, an unlikely coalition of religious, environmental and ani-
mal rights groups have raised a set of moral concerns. These groups attack 
the issue from different perspectives reflecting their own moral agendas, 
but they all reject the definition of animals as resources, or, in the language 
of patent law, “compositions of matter.” Jeremy Rifkin, a persistent critic of 
biotechnology research, has accused the U.S. Patent and Trademark Office 
of reducing “the entire animal kingdom of this planet to the lowly status of a 
commercial commodity—a technological product indistinguishable from 
electric toasters, automobiles, tennis balls, or any other patented product.” 
While most visible, Rifkin is not alone; indeed, his influence as a biotech-
nology “gadfly” reflects the wide appeal of his ideas. Representatives from 
an array of citizen’s groups are questioning the moral authority of scientists 
to alter the state of nature.
Although humans have owned and used animals for millennia, the idea 
of patented ownership has invited renewed scrutiny of the human-animal 
relationship. Animal rights group in the U.S. and in Western Europe are en-
joying extraordinary expansion and public visibility. They maintain that 
tinkering with an animal’s genes violated “species integrity” and, in typical 
animal rights language, “the inherent sanctity of every unique being and the
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recognition of the ecological and spiritual interconnectedness of life.” Ex-
pressing these assumptions at the Congressional hearing, John Barnes, a 
veterinarian testifying for the Alliance for Animals, suggested that animal 
ownership has traditionally implied the responsibility of stewardship. This 
responsibility would be lost with corporate ownership.
Animal rightists usually see themselves in conflict with those who es-
pouse a Judeo-Christian ethic supporting human domination over animals, 
but on this issue these groups concur. Reverend Wesley Granberg-Michael- 
son of the National Council of Churches said, “A real shift in how humanity 
relates to the natural environment is occurring when we face this issue.” 
From his religious perspective: “The Judeo-Christian view says that the 
Creation is, in essence, held in trust...We have a responsibility to see that its 
integrity is preserved.”
The notion of “species integrity” has raised the question of what is, or 
is not, natural. Genetic engineering, sanctioned by patents, seems to some a 
profoundly unnatural act. “We are engineering ourselves away from natural 
selection into a mechanical selection of traits," said Representative Charles 
Rose (D-NC), who had introduced legislation for a moratorium on animal 
patents. Granberg-Michaelson stated this idea in graphic terms: “Cows do 
not mate with fish. Humans do not mate with pigs. Fireflies do not mate 
with tobacco plants. These combinations are more than what can be called 
simply‘natural occurrences.’” Similarly, European activists have objected 
to the view of “living factories rather than sentient beings.” They reject the 
very principle of patenting of life as reflecting “a highly questionable rela-
tionship of Humanity to Nature.” It would “undermine any last thread of 
respect for nature in our already artificialized world...forcing upon us a re-
ductionist and materialistic concept of life.” Thus, this dimension of the de-
bate reflects fundamental philosophical differences concerning the essential 
nature of living beings.
Some concerns about biotechnology have focused more concretely on 
the effect of patenting on the research agenda and on the use of government 
supported science. Is it right that private biotechnology companies will 
profit by building on a base of publicly funded research? Will academic sci-
entists, in dealing closely with industry, be appropriately accountable for 
their work?
In the U.S. Congressional hearings, the president of the Farmers’ Milk 
Marketing Cooperative, addressed the issue of profit: “...if most of the re-
search and development costs in the production of some super animal have 
been paid for from public coffers, is it proper to grant a monopoly market 
position for giant corporations for 17 years? Furthermore, is all of this nec-
essary to promote alleged scientific progress?” In fact, current laws deliber-
ately encourage private exploitation of publicly funded research as the most 
effective means of diffusion; but this policy continues to confront opposition
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mainly from groups concerned about the general direction of technological 
change.
Many scientists favor the growing industry-university collaborations 
in commercially useful research. They minimize the risks of such ventures 
based on traditional assumptions about scientific neutrality and the ability 
of scientists to regulate themselves. They do not believe patenting would 
distort the research agenda of scientists which is shaped by intellectual in-
terests and controlled through peer review and the values of their scientific 
disciplines. Others, however, suspect that the profit motive would, indeed, 
affect research. Jack Doyle of the Environmental Policy Institute, suggested 
at the hearings that industry-university collaboration in research and de-
velopment “is worrisome because it blurs the roles of government as regula-
tor and the university as society’s natural arbiter and adviser.” Such col-
laboration would disturb the traditional checks and balances on scientific 
knowledge and its application and shape the direction of future research. 
Critics doubt the ability of scientists to control the direction and use of 
their own research. “Allowing patent protection at this time will sever the 
contact between research and the public interest,” said the Wisconsin Farm 
Unity Alliance. “It will mean that biotech corporations will be able to fi-
nance a much more accelerated level of research and development with little 
concern for the need to build public understanding and support and even 
less concern about meaningful regulation.” This view was especially trou-
bling in Europe where private industry funding of research in public insti-
tutions is a recent practice. Opponents fear the privatization of public re-
search and suspect that patenting would lead to restricted information ex-
change among scientists and further limit public access to scientific infor-
mation. They feel that only private industry would benefit.
E T H I C A L ,  E C O N O M I C  A N D  P O L I T I C A L  C O N C E R N S  
The patenting of animals has become a lightning rod for existing ethical, 
economic and political concerns in both the U.S. and Europe. It takes place 
when the plight of small farmers is a growing problem and technological 
changes in the farm community are a polarizing force. The issue has entered 
the public arena when animal rights groups are questioning the morality of 
vivisection and arguing against the instrumental values that allowed ani-
mals to be used as a resource. The decision also touches on controversial 
and widely publicized possibilities of commercializing human tissue for fe-
tal research and human body parts for organ transplantation. It feeds exist-
ing worries about the effect of proliferating industry-university collabora-
tions in biotechnology with their implications for the values of open scientific 
communication, professional responsibility and academic freedom.
The decision also resonates with the general uneasiness about genetic 
research which relates to vague, yet profound, fears of human genetic engi-
neering. One should not underestimate the depth of public feelings about
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tampering with genes. We have only to look at the long history of popular 
culture—films and science fiction—that play on the fear of radiation muta-
tion and genetic manipulation to discover its archetypal roots. Recall, for 
example, the series of classic horror films in the 1950s (e.g., The Fly, The 
Wasp) and their images of mutant monsters resulting from radiation and 
tampering with genes: ants, wasps, spiders, scorpions mutated into the size 
of 747s. In Europe, the discourse on genetic engineering is colored by im-
ages of Nazi eugenics and human experimentation. These fears contribute 
to the opposition to genetic engineering and its popular image as technol-
ogy out-of-control.
The biotechnology debate must be understood in the context of the 
many other policy controversies over science and technology, for example, 
over the practices of fetal research and animal experimentation, the teach-
ing of evolution in the schools, the burial of nuclear wastes and the effects 
of technology on the environment. Such controversies reflect fundamental, 
and sometimes irreconcilable, values that are not easily resolved. In the case 
of animal patenting disputes, the small farmer, economically committed to 
the family farm and ideologically convinced that it is “essential to the demo-
cratic way of life,” is not likely to be convinced that patenting is beneficial. 
Biotechnology is not the cause of the decline in family farming and a ban on 
animal patents would not reverse the trend. For some, this technology has 
come to symbolize the differential social and economic impacts of techno-
logical change. Similarly, arguments about the usefulness of transgenic ani-
mals for medicine and research are unlikely to stop the opposition of animal 
rights crusaders. Driven by anti-instrumental values and beliefs about the 
sanctity of nature, they are mobilized to oppose all use of animals as tools. 
They are particularly troubled by techniques of biotechnology that have 
blurred the boundaries between inert matter and living objects, techniques 
now recognized in law and reified by the decision to patent animals as living 
inventions.
Even the scientists who deny effects of commercialized research on the 
norms and practices of science base their position on fundamental beliefs 
about academic integrity. Convinced of the moral neutrality of science, they 
assert the ability of scientists to resist the lures of profit and to effectively 
regulate themselves. Though academic engagement in the development and 
diffusion of new technology surely weakens the credibility of the academy 
as an independent source of assessment, industry-university consortia in 
biotechnology have proliferated.
The controversy over biotechnology patents has developed out of a 
fundamental clash of moral values, conflicting visions of progress and com-
peting world views. Based on beliefs about equality and justice and reflect-
ing questions about the meaning of progress, such controversies cannot be 
resolved by simply assessing risk or claiming the necessity of greater com-
petitiveness. Nor, in democratic societies, can they be simply dismissed, for
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underlying protest is a troubling mistrust of the authorities responsible for 
technological development. A national survey conducted by the Office of 
Technology Assessment has indicated broad mistrust of the government’s 
role in regulating biotechnology. In disputes involving statements concern-
ing potential risks, Americans believe environmental groups over federal 
agencies by a margin of 63 percent to 26 percent. The picture is similar in 
Europe where opinion surveys carried out in the 12 member states of the 
EEC showed that 52 percent of the people trust environmental and con-
sumer organizations “to tell the truth about biotechnology and genetic en-
gineering.” Only 20 percent chose public authorities and 6 percent chose in-
dustry as trustworthy guides.
The critical questions, then, have to do with authority. Who should be 
making decisions about a technology with such broad economic, moral and 
political consequences? How can we develop policies for technology assess-
ment that would include broader concerns about new biotechnology prod-
ucts and processes? The critical challenge in both the U.S. and the EC is 
how to develop mechanisms for conflict resolution in the face of intuitive 
mistrust, competing economic visions and philosophical disagreement 
about the costs and benefits of new technologies and their differential effects.
Since the early 1970s, similar challenges have been expressed in dis-
putes over other technologies that present potential risks to health, envi-
ronment or social values. Opposition to nuclear power; protests against the 
siting of airports, toxic waste dumps, chemical plants and other noxious fa-
cilities; and fights over the rules and standards regulating pollution, began 
in the early 1970s—most have persisted for several decades. To resolve these 
disputes, public agencies in both the U.S. and Western Europe during the 
1970s encouraged greater public involvement in technological decisions on 
the assumption that this would foster public acceptance of technology and 
enhance the legitimacy of decision-making institutions. There followed a 
variety of efforts to involve citizens more directly in creating and imple-
menting policies for technological change.
These efforts ranged from broadly participative inquiries to environ-
mental mediation. They included complaint and consultation systems, citi-
zen advisory groups, representation of citizens in review boards and special 
issue referenda. Some were intended to develop consensus among conflict-
ing scientific groups as a means to advise decision-makers (e.g., science 
courts); others to educate the public. The process created depended on how 
the problem of public acceptance was defined. Where lack of public confi-
dence was thought to arise from technical uncertainties (for example, about 
risk), the goal was to develop a scientific consensus among dissenting 
groups in order to improve the advice available to decision-makers. Where 
problems of acceptance were attributed to lack of public understanding, the 
task became one of public education. Where controversy was defined in
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terms of alienation and mistrust, more participatory and consultative sys-
tems evolved.
The 1970s experiments had mixed success, depending in part on how 
realistically they defined the source of public opposition to technology poli-
cies. However, they helped to avoid the polarization and mistrust that is so 
evident in biotechnology disputes today. This polarization reflects, in part, 
the insistent focus on economic competitiveness as the central value over-
shadowing all other concerns—a focus that necessarily defines public par-
ticipation as an impediment to technological change. This attitude, how-
ever, has only served to exclude issues of public concern and increase public 
resentment. European groups, for example, feel that “the public is being 
kept out of the discussion, as if it were merely a technical matter. This must 
stop! The patenting of life is too important to leave up to a handful of ex-
perts and corporate lobbyists.”
C O N C L U S I O N
I conclude by extracting some principles from the 1970s struggles to estab-
lish effective negotiations for the resolution of technological disputes. We 
learned from these struggles that:
—Negotiations must deal directly with issues of public concern includ-
ing questions of ethics and equity as well as economics and risk. Thus, con-
troversial issues must be defined in terms of problems to be solved rather 
than solutions to be accepted. Proponents of a technology, determined to 
implement preconceived decisions, try to deal with protest by co-opting pub-
lic support rather than by expanding choice. Leaving little room for compro-
mise, these attitudes often resulted in the transfer of conflict from public 
hearings to the courts and sometimes to the streets.
—We learned that effective negotiation requires that participants have a 
sense of political efficacy and choice over the issues that most concern them. 
Establishing political efficacy rests on widely distributed knowledge and ac-
cess to expertise. High quality educational materials should be designed, not 
to promote the technology, but to open frank discussion and understanding 
of both benefits and costs. Thus, efforts to enhance the competence (and to 
avoid manipulation) of journalists is essential, for the media play a signifi-
cant role in informing the public.
—Finally, developing trust is a long-term process built on evidence of 
reliability and openness established over time. The emerging field of biotech-
nology offers opportunities for policy negotiation early in the development 
of the technology, before significant choices are made. These choices should 
not, at this early stage, be limited to narrow, short-term questions of risk.
The dispute over animal patents suggests that evaluation of the products and 
processes emerging from biotechnology must be developed with an eye to 
their differential social and economic impacts. The institutional procedures
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for assessing these impacts must also involve those who are affected and con-
cerned. The history of participatory procedures suggests this may not pro-
duce consensus; when technologies embody highly controversial political 
and social values, consensus is not a feasible goal. By sorting out conflicting 
values, they may reduce public mistrust of administrative institutions and, in 
the long run, encourage the development of equitable decisions.
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